-
The first exhibition of Hopstem Biotechnology at 2017 International Biomedical Innovation SummitAs a high-tech startup company in iPSCs disease modeling and drug screening platform area, Hopstem successfully held its first exhibition at the 2017 International Biomedical Innovation Summit. Besides showcases of our HopCell? products, we have also introduced our expertise in hiPSCs/hESCs differentiation, gene editing, cell banking and engineering, as well as new directions on cardio and liver cell differentiation. Our booth attracted a lot of attendees and many of them showed great interest wRead All
-
Congratulations！ Hopstem has been selected as “Eagle Plan” entrepreCongratulations to Hopstem! On Sep 13, Hopstem was listed as one of the “Eagle Plan” entrepreneurs of Hangzhou 2017.View details 2019-06-19 -
Congratulations! Hopstem enters the final competition (North American Division) of 2017 Hangzhou OveInitiated in March 2017, this competition has attracted 628 innovation projects from more than 20 countries in North America and Europe. After several rounds of screening and competition, Hopstem is among the 18 that are voted for the final competition of North American Division. Dr. Jing Fan, CEO of Hopstem, will participate in the live final in Silicon Valley on September 23, 2017.View details 2019-06-18 -
Congratulations! Hopstem received 1.8 million angel investments from three ventures in ChinaIn June 2017, Hopstem completed the angel fund seeking mission of 12 million RMB. This round of investment was led by HEDA Ventures, with Empower investment,CybernautInvestmentfollowed as the secondary investors. The 12 million funds will be spent on setting up a 9000 square feet GLP/GMP facility in Hangzhou (with GradeB clean room for cell cultures), hiring, manufacturing and marketing.View details 2019-06-18